Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Diabetic Macular Edema Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Diabetic Macular Edema Overview | 14 | 1 |
| Pipeline Products for Diabetic Macular Edema Comparative Analysis | 15 | 1 |
| Diabetic Macular Edema Therapeutics under Development by Companies | 16 | 4 |
| Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Diabetic Macular Edema Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Diabetic Macular Edema Products under Development by Companies | 25 | 3 |
| Diabetic Macular Edema Products under Investigation by Universities/Institutes | 28 | 1 |
| Diabetic Macular Edema Companies Involved in Therapeutics Development | 29 | 37 |
| Aciont Inc. | 29 | 1 |
| ActiveSite Pharmaceuticals, Inc. | 30 | 1 |
| Adverum Biotechnologies, Inc. | 31 | 1 |
| Aerpio Therapeutics, Inc. | 32 | 1 |
| Allergan Plc | 33 | 1 |
| Ampio Pharmaceuticals, Inc. | 34 | 1 |
| Araim Pharmaceuticals, Inc. | 35 | 1 |
| Astellas Pharma Inc. | 36 | 1 |
| Boehringer Ingelheim GmbH | 37 | 1 |
| Chengdu Kanghong Pharmaceuticals Group Co., Ltd. | 38 | 1 |
| Clonz Biotech Private Limited | 39 | 1 |
| 7 Coherus BioSciences, Inc. | 40 | 1 |
| EyeGate Pharmaceuticals, Inc. | 41 | 1 |
| EyeGene, Inc. | 42 | 1 |
| F. Hoffmann-La Roche Ltd. | 43 | 1 |
| Formycon AG | 44 | 1 |
| Genmab A/S | 45 | 1 |
| Icon Bioscience, Inc. | 46 | 1 |
| Kala Pharmaceuticals, Inc. | 47 | 1 |
| Kalvista Pharmaceuticals Ltd | 48 | 1 |
| Kowa Company, Ltd. | 49 | 1 |
| Mabion SA | 50 | 1 |
| NicOx S.A. | 51 | 1 |
| Oculis ehf | 52 | 1 |
| Ohr Pharmaceutical Inc. | 53 | 1 |
| Pfizer Inc. | 54 | 1 |
| Precision Ocular Ltd | 55 | 1 |
| pSivida Corp. | 56 | 1 |
| Regeneron Pharmaceuticals, Inc. | 57 | 1 |
| Santen Pharmaceutical Co., Ltd. | 58 | 1 |
| SciFluor Life Sciences, LLC | 59 | 1 |
| Senju Pharmaceutical Co., Ltd. | 60 | 1 |
| Stealth BioTherapeutics Inc. | 61 | 1 |
| Sucampo Pharmaceuticals, Inc. | 62 | 1 |
| ThromboGenics NV | 63 | 1 |
| Verseon Corporation | 64 | 1 |
| Xbrane Biopharma AB | 65 | 1 |
| Diabetic Macular Edema Therapeutics Assessment | 66 | 12 |
| Assessment by Monotherapy Products | 66 | 1 |
| Assessment by Combination Products | 67 | 1 |
| Assessment by Target | 68 | 3 |
| Assessment by Mechanism of Action | 71 | 3 |
| Assessment by Route of Administration | 74 | 2 |
| Assessment by Molecule Type | 76 | 2 |
| Drug Profiles | 78 | 102 |
| (aflibercept + nesvacumab) Drug Profile | 78 | 1 |
| abicipar pegol Drug Profile | 79 | 3 |
| ACX-107 Drug Profile | 82 | 1 |
| aflibercept biosimilar Drug Profile | 83 | 1 |
| AKB-9778 Drug Profile | 84 | 4 |
| ALG-1001 Drug Profile | 88 | 3 |
| Antibodies to Inhibit Hemopexin for Diabetic Macular Edema Drug Profile | 91 | 1 |
| ASP-440 Drug Profile | 92 | 1 |
| ASP-8232 Drug Profile | 93 | 1 |
| ASPPDC-010 Drug Profile | 94 | 1 |
| AVA-101 Drug Profile | 95 | 3 |
| BI-1026706 Drug Profile | 98 | 1 |
| Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications Drug Profile | 99 | 1 |
| cibinetide Drug Profile | 100 | 3 |
| conbercept Drug Profile | 103 | 2 |
| danazol Drug Profile | 105 | 4 |
| dexamethasone acetate Drug Profile | 109 | 4 |
| dexamethasone acetate Drug Profile | 113 | 1 |
| dexamethasone dipropionate Drug Profile | 114 | 1 |
| dexamethasone dipropionate XR Drug Profile | 115 | 1 |
| difluprednate Drug Profile | 116 | 1 |
| Drug for Diabetic Macular Edema Drug Profile | 117 | 1 |
| Drugs for Retinal Diseases Drug Profile | 118 | 1 |
| EBI-031 Drug Profile | 119 | 1 |
| EG-Mirotin Drug Profile | 120 | 1 |
| elamipretide Drug Profile | 121 | 7 |
| fluocinolone acetonide SR Drug Profile | 128 | 8 |
| JDE-006 Drug Profile | 136 | 1 |
| KVD-001 Drug Profile | 137 | 1 |
| loteprednol etabonate Drug Profile | 138 | 3 |
| NCX-422 Drug Profile | 141 | 1 |
| NCX-434 Drug Profile | 142 | 2 |
| NM-108 Drug Profile | 144 | 1 |
| OLX-303 Drug Profile | 145 | 1 |
| PF-655 Drug Profile | 146 | 3 |
| ranibizumab biosimilar Drug Profile | 149 | 1 |
| ranibizumab biosimilar Drug Profile | 150 | 2 |
| ranibizumab biosimilar Drug Profile | 152 | 1 |
| ranibizumab biosimilar Drug Profile | 153 | 1 |
| ranibizumab biosimilar Drug Profile | 154 | 1 |
| RC-1 Alpha Drug Profile | 155 | 1 |
| ripasudil Drug Profile | 156 | 2 |
| RTU-1096 Drug Profile | 158 | 2 |
| SF-0166 Drug Profile | 160 | 1 |
| Small Molecule for Diabetic Macular Edema Drug Profile | 161 | 1 |
| Small Molecule to Inhibit Kallikrein for Diabetic Macular Edema Drug Profile | 162 | 1 |
| Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema Drug Profile | 163 | 1 |
| Small Molecules to Inhibit Plasma Kallikrein for DME and HAE Drug Profile | 164 | 2 |
| squalamine lactate Drug Profile | 166 | 8 |
| teprotumumab Drug Profile | 174 | 2 |
| TG-931 Drug Profile | 176 | 1 |
| THR-149 Drug Profile | 177 | 1 |
| triamcinolone acetonide Drug Profile | 178 | 1 |
| VA-999272 Drug Profile | 179 | 1 |
| Diabetic Macular Edema Dormant Projects | 180 | 3 |
| Diabetic Macular Edema Discontinued Products | 183 | 1 |
| Diabetic Macular Edema Product Development Milestones | 184 | 10 |
| Featured News &Press Releases | 184 | 1 |
| Jul 07, 2016: Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 | 184 | 1 |
| Jun 13, 2016: Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial | 184 | 1 |
| May 11, 2016: Alimera Sciences' ILUVIEN Data Presented at SFO 2016 | 185 | 1 |
| May 10, 2016: Queens University Belfast to study the Innate Repair Activator ARA 290 in Diabetic Macular Edema | 185 | 1 |
| May 06, 2016: Alimera Sciences ILUVIEN Data Presented At 2016 ARVO | 186 | 1 |
| Apr 29, 2016: Eleven Biotherapeutics to Present Data on EBI-031 at the ARVO 2016 Annual Meeting | 187 | 1 |
| Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease | 188 | 1 |
| Jan 26, 2016: Ampio OptimEyes Study Results to be presented at The Association for Research in Vision and Ophthalmology (ARVO) | 188 | 1 |
| Jan 15, 2016: Eleven Biotherapeutics provides an update for EBI-031 | 189 | 1 |
| Jan 05, 2016: Allegro Ophthalmics Announces Last Patient Enrolled in Del Mar Phase 2b Clinical Trial of Luminate for the Treatment of Diabetic Macular Edema | 190 | 1 |
| Jan 04, 2016: Alimera Sciences Announces ILUVIEN J Code J7313 Is Now Active | 190 | 1 |
| Nov 16, 2015: Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN Slows Diabetic Retinopathy Progression | 191 | 1 |
| Nov 13, 2015: Allergan Presents EARLY Analysis Data at the American Academy of Ophthalmology Annual Meeting | 191 | 1 |
| Oct 14, 2015: Ampio Pharmaceuticals Announces Updates On the Regulatory Path for FDA Approval of Optina, an Oral Treatment for Diabetic Macular Edema | 192 | 1 |
| Oct 09, 2015: Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day | 193 | 1 |
| Appendix | 194 | 2 |
| Methodology | 194 | 1 |
| Coverage | 194 | 1 |
| Secondary Research | 194 | 1 |
| Primary Research | 194 | 1 |
| Expert Panel Validation | 194 | 1 |
| Contact Us | 194 | 1 |
| Disclaimer | 195 | 1 |